Previous 10 | Next 10 |
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes and other important biochemical substances through the skin NEW YORK, Nov. 14, 2019 (G...
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the ȁ...
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the No...
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical dev...
Editor's note: Seeking Alpha is proud to welcome Steven Grandstaff as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Background and...
PAVmed Inc. (PAVM) Q2 2019 Earnings Conference Call September 05, 2019 4:30 PM ET Company Participants Mike Havrilla - Director of Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - President & Chief Financial Officer Conference Call ...
PAVmed (NASDAQ: PAVM ): Q2 GAAP EPS of -$0.13 misses by $0.03 . More news on: PAVmed Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reporte...
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 10,...
All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...